Navigation Links
Pipeline Initiatives, Partnerships to Drive Growth - Research Report on Pfizer, Theravance, ISIS Pharmaceuticals, Infinity Pharmaceuticals and Ironwood
Date:3/7/2013

NEW YORK, March 7, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Theravance Inc (NASDAQ: THRX), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), Infinity Pharmaceuticals Inc. (NASDAQ: INFI) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

Pfizer recently presented the results from the Phase 3 study of Prevnar 13 in adults infected with HIV at the 20th Conference on Retroviruses and Opportunistic Infections (CROI). The study demonstrated the drug's immunogenicity, tolerability and safety. The research was made to minimize the threat of infectious diseases to adults with weakened immune systems. Two weeks ago, Pfizer also presented results for a Phase 3 study showing Lyrica's efficacy as an adjunctive therapy in adult epilepsy patients experiencing partial seizures. With a highly active R&D department presenting positive results, Pfizer is continuing to strengthen its pipeline and improve its prospects. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/e0bd_PFE]

--

Theravance Inc Research Report

Theravance shares rallied by as much as 18 percent after a Piper Jaffray analyst said that the approval Therevance's respiratory drugs could lead to a takeover by GlaxoSmithKline. Theravance is co-developing Breo and Anoro with GlaxoSmithKline, drugs that treat chronic respiratory diseases. The FDA is scheduled to review Breo on Thursday and is expected to give their final decision on May 12. The final decision for Anoro is due on December 12. Whether or not GlaxoSmithKline decides to buy Theravance, Breo sales are still expected total around $314 million in 2014 and grow to about $1.25 billion by 2017 if the drug is approved this year, according to Thomson Pharma. With two pending drug approvals and a potential buyout from Britain's biggest drug maker, the outlook for Theravance looks bright. The Full Research Report on Theravance Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/b77f_THRX]

--

ISIS Pharmaceuticals, Inc. Research Report

ISIS Pharmaceuticals recently reported its 2012 financial results. The company highlighted NOL of $60.4 million compared to $61.3 million in 2011.The FDA approval of KYNAMRO, the first systemic antisense drug, was one of the highlights. In addition, ISIS Pharmaceuticals expects to report late-stage clinical data on promising new drugs within the year. Moving forward, ISIS expects to further advance its pipeline and also expects Genzyme to help push KYNAMRO's commercial success. ISIS Pharmaceuticals' ongoing partnerships with leading drug makers remain encouraging. The Full Research Report on ISIS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/bf5f_ISIS]

--

Infinity Pharmaceuticals Inc. Research Report

Shares of Infinity Pharmaceuticals jumped after a Piper Jaffray analyst claimed that the company's experimental drug will be approved to treat several types of cancer, with annual sales of $3 billion. Analyst Ian Somaiya initiated coverage on Infinity Pharmaceuticals shares with an "Overweight" rating and expects the shares to rise higher after the company reports results from early clinical trials of the drug IPI-145. Another drug that Infinity is developing is IPI-504. Many are already expecting massive long-term growth for Infinity after its drugs finish trials around 2019, driven by a promising pipeline. The Full Research Report on Infinity Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/d603_INFI]

--

Ironwood Pharmaceuticals, Inc. Research Report

Ironwood recently appointed Edward Owens , a recently retired partner, portfolio manager and global industry analyst with Wellington Management Company to its Board of Directors. Mr. Owens comments that Ironwood will be one of the next growth companies in biotech. Furthermore, he asserts that Ironwood's successful launch of LINZESS should provide Ironwood what it needs to build an exceptional business. Moving forward, Ironwood will focus on further increasing the sales of LINZESS and strengthening the clinical profile of Constella, the treatment of moderate to severe irritable bowel syndrome. Its pipeline includes IW-9179 for functional dyspepsia and IW-2143 for anxiety. By advancing its pipeline, Ironwood is set to reach its goal of providing differentiated medicines and deliver for investors. The Full Research Report on Ironwood Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/ec5d_IRWD]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.

Contact: Patricia Byers
Email: press@Investors-Alliance.com
Main: +1-480-745-7826


'/>"/>
SOURCE Investors-Alliance
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
4. Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
5. Drug Discovery Technologies Market Soars to $79 billion by 2017, Driven by Innovations in Pipeline and Tools Development
6. Negative Pressure Wound Therapy (NPWT) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
7. Demand for Product Pipeline Review and Analysis Rises in the Global Pharma Industry
8. Whats Next In Vaccines (Malaria, Diabetes, Alzheimers, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline)
9. Sports Medicine Implants Market - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
10. Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
11. Radiation Therapy in Oncology Drug Pipeline Update 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences Ltd. ... specializing in the development of cannabinoid-based drugs, today ... company overview at three upcoming scientific and investor ... LD Micro Invitational: ... Date:                     ...
(Date:5/26/2017)... BARBARA, Calif. , May 25, 2017  In ... United States , Direct Relief is working with ... overdose-reversing Naloxone available at no cost to community health ... other nonprofit providers nationwide. "Pfizer has ... access to medicines and ensuring patient safety through educational ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, ... Gene-Eden-VIR/Novirin, announces the launch of a new ... the results of a clinical study that showed ... treatment with Gene-Eden-VIR/Novirin in individuals suffering from HPV ... note that there are no other treatments that ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... The Katyl Agency, a locally ... and business owners in and around Lackawanna County, is joining Meals On Wheels ... area. , Meals on Wheels of NEPA provides hand-delivered and nutritious meals to ...
(Date:6/22/2017)... ... 2017 , ... Branches, Inc. has been partnering with The Miami Foundation for ... its programs focused on providing opportunity to low-income families and breaking the cycle of ... of $15,000 to support its , Climb to College & Career initiative which focuses ...
(Date:6/22/2017)... ... June 23, 2017 , ... Despite its pervasiveness, many physicians are unfamiliar ... integrate basic science with clinical practice. Now, however, a timely review has been published ... insight into the etiology of NeuP and educating preclinical scientists on its diagnosis and ...
(Date:6/20/2017)... Murfreesboro, Tennessee (PRWEB) , ... June 20, 2017 ... ... chronic care services, announced today that Claritas Capital, a Nashville-based private equity firm, ... to accelerate our expansion plans for some time, and Claritas Capital offers the ...
(Date:6/20/2017)... ... June 20, 2017 , ... Hayes, Inc., a leading ... eBook titled “ 5 Questions to Ask Before Entering the Maze of Genetic ... Test Evaluation (GTE) team, the book explores the various types of the more ...
Breaking Medicine News(10 mins):